About Abaxis (NASDAQ:ABAX)
Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in human or veterinary patient care settings to provide rapid blood constituent measurements for clinicians worldwide. It operates in two segments, Medical Market and Veterinary Market. The company offers Piccolo chemistry analyzers with rapid blood constituent measurements for use in human patient care; and Piccolo profiles that are single-use medical reagents. It also provides VetScan VS2, a chemistry, electrolyte, immunoassay, and blood gas analyzer delivering results from a sample of whole blood, serum, or plasma; VetScan profiles, which are packaged as single-use plastic veterinary reagent discs; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, as well as reagent kits for veterinary applications. In addition, the company offers VetScan VSpro that assists the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, disseminated intravascular coagulation evaluation, hepatic disease, monitoring therapy, and disease progression states; VetScan VSpro coagulation test to evaluate prothrombin and the activated partial thromboplastin times; VetScan VSpro fibrinogen test for in-vitro determination of fibrinogen levels in equine platelet poor plasma from a citrated stabilized whole blood sample; and i-STAT that delivers blood gas, electrolyte, chemistry, and hematology results. Further, it provides VetScan rapid tests for the detection of various diseases, as well as sells products developed through its patented Orbos discrete lyophilization process to companies for other applications. The company sells its products through direct sales force and independent distributors. Abaxis, Inc. was founded in 1989 and is headquartered in Union City, California.
Industry, Sector and Symbol
Industry Measuring & controlling devices, not elsewhere classified
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABAX
CUSIP00256710
Phone510-675-6500
Debt
Debt-to-Equity RatioN/A
Current Ratio5.92%
Quick Ratio4.92%
Price-To-Earnings
Trailing P/E Ratio57.28
Forward P/E Ratio62.71
P/E Growth9.98
Sales & Book Value
Annual Sales$227.22 million
Price / Sales7.27
Cash Flow$1.6251 per share
Price / Cash44.76
Book Value$11.81 per share
Price / Book6.16
Profitability
EPS (Most Recent Fiscal Year)$1.27
Net Income$32.71 million
Net Margins10.51%
Return on Equity10.09%
Return on Assets8.69%
Miscellaneous
Employees584
Outstanding Shares22,700,000
Abaxis (NASDAQ:ABAX) Frequently Asked Questions
What is Abaxis' stock symbol?
Abaxis trades on the NASDAQ under the ticker symbol "ABAX."
How often does Abaxis pay dividends? What is the dividend yield for Abaxis?
Abaxis declared a quarterly dividend on Thursday, January 25th. Shareholders of record on Thursday, March 1st will be paid a dividend of $0.16 per share on Thursday, March 15th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Wednesday, February 28th. View Abaxis' Dividend History.
How will Abaxis' stock buyback program work?
Abaxis announced that its Board of Directors has initiated a stock buyback program on Wednesday, October 25th 2017, which permits the company to repurchase $21,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's leadership believes its shares are undervalued.
How were Abaxis' earnings last quarter?
Abaxis (NASDAQ:ABAX) announced its quarterly earnings results on Thursday, January, 25th. The medical research company reported $0.31 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.26 by $0.05. The medical research company earned $59.70 million during the quarter, compared to analysts' expectations of $59.37 million. Abaxis had a net margin of 10.51% and a return on equity of 10.09%. The company's revenue for the quarter was up 13.1% on a year-over-year basis. During the same period last year, the firm earned $0.30 earnings per share. View Abaxis' Earnings History.
When is Abaxis' next earnings date?
What price target have analysts set for ABAX?
7 brokers have issued 12 month price objectives for Abaxis' shares. Their predictions range from $48.00 to $65.00. On average, they expect Abaxis' share price to reach $56.6250 in the next year. View Analyst Ratings for Abaxis.
Who are some of Abaxis' key competitors?
Some companies that are related to Abaxis include Array Biopharma (ARRY), Amn Healthcare Services (AMN), UDG Healthcare (UDHCF), Spark Therapeutics (ONCE), Inogen (INGN), Tesaro (TSRO), Indivior (INDV), China Biologic Products (CBPO), Clovis Oncology (CLVS), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), Immunomedics (IMMU), Amicus Therapeutics (FOLD), Nevro (NVRO), Foundation Medicine (FMI), Magellan Health (MGLN), Emergent BioSolutions (EBS) and Ultragenyx Pharmaceutical (RARE).
Who are Abaxis' key executives?
Abaxis' management team includes the folowing people:
- Mr. Clinton H. Severson, Chairman & CEO (Age 70)
- Mr. Donald P. Wood, Pres & COO (Age 66)
- Mr. Ross Taylor Jr., CFO, Principal Accounting Officer, VP of Fin. & Sec. (Age 55)
- Dr. Kenneth P. Aron Ph.D., Chief Technology Officer (Age 65)
- Dr. Craig M. Tockman DVM, VP of Animal Health Sales and Marketing - North America (Age 58)
Has Abaxis been receiving favorable news coverage?
Media stories about ABAX stock have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Abaxis earned a news impact score of 0.16 on Accern's scale. They also assigned media headlines about the medical research company an impact score of 46.53 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Who are Abaxis' major shareholders?
Abaxis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include
PRIMECAP MANAGEMENT COMPANY
(9.77%). Company insiders that own Abaxis stock include Achim Henkel, Clinton Severson, Craig Tockman, Donald Peter Wood, Henk Evenhuis, Kenneth Aron, Michael D Casey, Prithipal Singh and Richard Bastiani. View Institutional Ownership Trends for Abaxis.
How do I buy shares of Abaxis?
Shares of ABAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abaxis' stock price today?
One share of ABAX stock can currently be purchased for approximately $72.74.
How big of a company is Abaxis?
Abaxis has a market capitalization of $1.67 billion and generates $227.22 million in revenue each year. The medical research company earns $32.71 million in net income (profit) each year or $1.27 on an earnings per share basis. Abaxis employs 584 workers across the globe.
How can I contact Abaxis?
Abaxis' mailing address is 3240 WHIPPLE ROAD, UNION CITY CA, 94587. The medical research company can be reached via phone at 510-675-6500 or via email at [email protected]
MarketBeat Community Rating for Abaxis (ABAX)
MarketBeat's community ratings are surveys of what our community members think about Abaxis and other stocks. Vote "Outperform" if you believe ABAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Abaxis (NASDAQ:ABAX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Abaxis in the last 12 months. Their average twelve-month price target is $56.6250, suggesting that the stock has a possible downside of 22.15%. The high price target for ABAX is $65.00 and the low price target for ABAX is $48.00. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.13 | 2.00 |
| Ratings Breakdown: | 1 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $56.6250 | $56.6250 | $49.6250 | $48.6250 |
| Price Target Upside: | 22.15% downside | 11.79% downside | 20.52% downside | 3.28% upside |
Abaxis (NASDAQ:ABAX) Consensus Price Target History
Abaxis (NASDAQ:ABAX) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Abaxis (NASDAQ:ABAX) Dividend Information
Abaxis pays an annual dividend of $0.64 per share, with a dividend yield of 0.88%. ABAX's most recent quarterly dividend payment was Thursday, March 15. Abaxis pays out 50.39% of its earnings out as a dividend.
| Most Recent Dividend: | 3/15/2018 |
| Annual Dividend: | $0.64 |
| Dividend Yield: | 0.88% |
| Payout Ratio: | 50.39% (Trailing 12 Months of Earnings)
55.17% (Based on This Year's Estimates)
43.84% (Based on Next Year's Estimates)
|
Abaxis (NASDAQ:ABAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 1/25/2018 | quarterly | $0.16 | 0.91% | 2/28/2018 | 3/1/2018 | 3/15/2018 |
| 10/24/2017 | quarterly | $0.16 | 1.28% | 11/30/2017 | 12/1/2017 | 12/15/2017 |
| 7/27/2017 | quarterly | $0.14 | 1.19% | 8/30/2017 | 9/1/2017 | 9/15/2017 |
| 4/27/2017 | quarterly | $0.14 | 1.24% | 5/30/2017 | 6/1/2017 | 6/15/2017 |
| 1/26/2017 | quarterly | $0.14 | 1.13% | 2/27/2017 | 3/1/2017 | 3/15/2017 |
| 10/28/2016 | quarterly | $0.14 | 1.17% | 11/29/2016 | 12/1/2016 | 12/15/2016 |
| 7/21/2016 | quarterly | $0.12 | 1.04% | 8/30/2016 | 9/1/2016 | 9/15/2016 |
| 4/28/2016 | quarterly | $0.12 | 1.06% | 6/1/2016 | 6/3/2016 | 6/17/2016 |
| 1/28/2016 | quarterly | $0.11 | 1.01% | 3/1/2016 | 3/3/2016 | 3/17/2016 |
| 11/3/2015 | quarterly | $0.11 | 0.84% | 12/1/2015 | 12/3/2015 | 12/17/2015 |
| 7/23/2015 | quarterly | $0.11 | 0.9% | 9/1/2015 | 9/3/2015 | 9/17/2015 |
| 4/30/2015 | quarterly | $0.11 | 0.79% | 6/2/2015 | 6/4/2015 | 6/18/2015 |
| 1/30/2015 | quarterly | $0.10 | 0.65% | 2/27/2015 | 3/3/2015 | 3/17/2015 |
| 10/23/2014 | quarterly | $0.10 | 0.82% | 11/13/2014 | 11/17/2014 | 12/16/2014 |
| 7/24/2014 | quarterly | $0.10 | 0.86% | 8/29/2014 | 9/3/2014 | 9/17/2014 |
| 4/24/2014 | quarterly | $0.10 | | 5/30/2014 | 6/3/2014 | 6/17/2014 |
| 12/6/2012 | special | $1.00 | | 12/13/2012 | 12/17/2012 | 12/28/2012 |
(Data available from 1/1/2013 forward)
Abaxis (NASDAQ ABAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 99.32%
Abaxis (NASDAQ ABAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/8/2018 | Michael D Casey | Director | Sell | 5,000 | $71.07 | $355,350.00 | 27,290 |  |
| 3/6/2018 | Donald Peter Wood | COO | Sell | 10,000 | $68.99 | $689,900.00 | | |
| 3/6/2018 | Kenneth Aron | Insider | Sell | 1,412 | $69.59 | $98,261.08 | | |
| 3/6/2018 | Prithipal Singh | Director | Sell | 2,000 | $70.25 | $140,500.00 | | |
| 2/27/2018 | Achim Henkel | Insider | Sell | 3,600 | $69.08 | $248,688.00 | 57,650 | |
| 1/31/2018 | Craig Tockman | VP | Sell | 1,650 | $74.33 | $122,644.50 | 10,866 | |
| 1/31/2018 | Prithipal Singh | Director | Sell | 2,000 | $74.63 | $149,260.00 | 44,000 | |
| 5/26/2017 | Achim Henkel | Insider | Sell | 650 | $48.87 | $31,765.50 | 58,950 | |
| 5/8/2017 | Achim Henkel | Director | Sell | 8,650 | $47.75 | $413,037.50 | 68,150 | |
| 2/2/2017 | Richard Bastiani | Director | Sell | 4,000 | $51.12 | $204,480.00 | 49,178 | |
| 12/6/2016 | Clinton Severson | CEO | Sell | 15,000 | $51.35 | $770,250.00 | 562,300 | |
| 12/2/2016 | Kenneth Aron | Insider | Sell | 5,000 | $51.09 | $255,450.00 | 92,151 | |
| 9/9/2016 | Clinton Severson | CEO | Sell | 2,000 | $48.29 | $96,580.00 | 574,691 | |
| 9/8/2016 | Prithipal Singh | Director | Sell | 1,000 | $49.50 | $49,500.00 | 42,500 | |
| 8/25/2016 | Prithipal Singh | Director | Sell | 1,500 | $50.30 | $75,450.00 | 43,500 | |
| 8/24/2016 | Donald Peter Wood | Insider | Sell | 8,500 | $50.21 | $426,785.00 | 52,618 | |
| 6/9/2016 | Richard Bastiani | Director | Sell | 5,000 | $46.75 | $233,750.00 | 54,400 | |
| 5/17/2016 | Achim Henkel | Director | Sell | 5,000 | $44.43 | $222,150.00 | 53,609 | |
| 5/9/2016 | Henk Evenhuis | Director | Sell | 3,000 | $45.00 | $135,000.00 | 15,400 | |
| 2/9/2016 | Vernon E Altman | Director | Buy | 303 | $39.87 | $12,080.61 | 16,303 | |
| 12/8/2015 | Craig Tockman | VP | Sell | 560 | $54.44 | $30,486.40 | 1,189 | |
| 2/9/2015 | Prithipal Singh | Director | Sell | 2,500 | $60.50 | $151,250.00 | | |
| 12/8/2014 | Kenneth Aron | CTO | Sell | 2,000 | $56.68 | $113,360.00 | | |
| 11/25/2014 | Clinton Severson | CEO | Sell | 2,286 | $56.00 | $128,016.00 | | |
| 11/13/2014 | Clinton Severson | CEO | Sell | 10,000 | $55.00 | $550,000.00 | | |
| 11/5/2014 | Clinton Severson | CEO | Sell | 10,000 | $54.00 | $540,000.00 | | |
| 11/3/2014 | Alberto Santa Ines | CFO | Sell | 1,652 | $53.09 | $87,704.68 | | |
| 11/3/2014 | Clinton Severson | CEO | Sell | 5,000 | $53.00 | $265,000.00 | | |
| 10/31/2014 | Clinton Severson | CEO | Sell | 10,000 | $51.50 | $515,000.00 | | |
| 8/12/2014 | Richard Bastiani | Director | Sell | 1,000 | $45.40 | $45,400.00 | | |
| 7/30/2014 | Alberto Santa Ines | CFO | Sell | 10,738 | $47.81 | $513,383.78 | | |
| 7/29/2014 | Alberto Santa Ines | CFO | Sell | 17,293 | $48.01 | $830,236.93 | | |
| 6/5/2014 | Richard Bastiani | Director | Sell | 2,000 | $42.10 | $84,200.00 | | |
| 6/3/2014 | Richard Bastiani | Director | Sell | 4,000 | $41.88 | $167,520.00 | | |
| 5/22/2014 | Achim Henkel | Director | Sell | 8,500 | $41.63 | $353,855.00 | | |
| 5/14/2014 | Henk Evenhuis | Director | Sell | 4,000 | $44.06 | $176,240.00 | 10,400 | |
| 5/1/2014 | Henk Evenhuis | Director | Sell | 4,500 | $41.00 | $184,500.00 | 14,400 | |
| 3/4/2014 | Vladimir Ostoich | VP | Sell | 9,800 | $38.53 | $377,594.00 | 381,987 | |
| 2/24/2014 | Kenneth Aron | CTO | Sell | 1,000 | $38.98 | $38,980.00 | 64,330 | |
| 2/13/2014 | Donald Peter Wood | COO | Sell | 8,864 | $38.50 | $341,264.00 | 20,634 | |
| 6/7/2013 | Clinton Severson | CEO | Sell | 10,000 | $44.50 | $445,000.00 | | |
| 6/7/2013 | Martin Mulroy | Insider | Sell | 14,000 | $44.80 | $627,200.00 | | |
| 5/22/2013 | Kenneth Aron | CTO | Sell | 4,200 | $43.28 | $181,776.00 | | |
| 5/7/2013 | Achim Henkel | Director | Sell | 5,000 | $44.07 | $220,350.00 | | |
| 3/1/2013 | Achim Henkel | Director | Sell | 1,000 | $42.85 | $42,850.00 | | |
| 2/26/2013 | Martin Mulroy | Insider | Sell | 12,000 | $41.84 | $502,080.00 | | |
| 2/5/2013 | Kenneth Aron | CTO | Sell | 40,000 | $44.13 | $1,765,200.00 | | |
| 2/4/2013 | Martin Mulroy | Insider | Sell | 12,000 | $43.97 | $527,640.00 | | |
| 11/23/2012 | Richard Bastiani | Director | Sell | 5,000 | $36.60 | $183,000.00 | | |
(Data available from 1/1/2013 forward)
Abaxis (NASDAQ ABAX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Abaxis To Report Fourth Quarter And Fiscal Year 2018 Financial Results On Thursday, April 26, 2018
finance.yahoo.com - April 20 at 9:34 AM |
 | $67.03 Million in Sales Expected for Abaxis (ABAX) This Quarter
www.americanbankingnews.com - April 19 at 4:27 AM |
| Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
finance.yahoo.com - April 18 at 4:48 PM |
| Abaxis (ABAX) to Release Earnings on Wednesday
www.americanbankingnews.com - April 18 at 1:52 AM |
| $0.32 Earnings Per Share Expected for Abaxis (ABAX) This Quarter
www.americanbankingnews.com - April 17 at 8:00 AM |
| Abaxis (ABAX) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - April 15 at 8:37 AM |
| Abaxis (ABAX) Downgraded by BidaskClub to "Buy"
www.americanbankingnews.com - April 13 at 5:29 PM |
| Here's Why You Should Steer Clear of AmerisourceBergen Now
finance.yahoo.com - April 13 at 4:33 PM |
| Abaxis Inc (ABAX) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - April 11 at 9:19 PM |
| Here's Why You Should Hold on to Varian Medical Stock Now
finance.yahoo.com - April 10 at 9:47 AM |
| Abaxis (ABAX) PT Lowered to $39.00 at Bank of America
www.americanbankingnews.com - April 5 at 12:39 PM |
| Abaxis (ABAX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 4 at 7:58 PM |
| Abaxis (ABAX) Upgraded at ValuEngine
www.americanbankingnews.com - April 3 at 8:12 PM |
| Abaxis (ABAX) Upgraded by Zacks Investment Research to "Strong-Buy"
www.americanbankingnews.com - April 3 at 2:59 PM |
| $67.03 Million in Sales Expected for Abaxis Inc (ABAX) This Quarter
www.americanbankingnews.com - April 2 at 4:00 AM |
| Brokerages Anticipate Abaxis Inc (ABAX) Will Announce Earnings of $0.32 Per Share
www.americanbankingnews.com - March 31 at 9:46 AM |
| Abaxis (ABAX) Upgraded at Raymond James Financial
www.americanbankingnews.com - March 29 at 11:52 PM |
| Abaxis (ABAX) Upgraded by UBS to Market Perform
www.americanbankingnews.com - March 29 at 11:18 PM |
| Canaccord Genuity Reiterates Hold Rating for Abaxis (ABAX)
www.americanbankingnews.com - March 28 at 12:58 PM |
| Abaxis (ABAX) Upgraded to "Hold" by BidaskClub
www.americanbankingnews.com - March 26 at 3:13 PM |
| Abaxis Inc (ABAX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 17 at 9:28 PM |
| Head to Head Comparison: Amedica (AMDA) and Abaxis (ABAX)
www.americanbankingnews.com - March 17 at 5:20 AM |
| Abaxis Inc Expected to Post Q3 2019 Earnings of $0.33 Per Share (ABAX)
www.americanbankingnews.com - March 16 at 1:56 PM |
| Northcoast Research Equities Analysts Boost Earnings Estimates for Abaxis Inc (ABAX)
www.americanbankingnews.com - March 15 at 9:40 AM |
 | Form 4 ABAXIS INC For: Mar 08 Filed by: CASEY MICHAEL D
www.streetinsider.com - March 12 at 11:08 AM |
| Abaxis (ABAX) and Varian Medical Systems (VAR) Critical Comparison
www.americanbankingnews.com - March 11 at 10:34 PM |
| Insider Selling: Abaxis Inc (ABAX) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - March 9 at 9:28 PM |
| See what the IHS Markit Score report has to say about Abaxis Inc.
finance.yahoo.com - March 9 at 9:53 AM |
| Insider Selling: Abaxis Inc (ABAX) Director Sells 2,000 Shares of Stock
www.americanbankingnews.com - March 8 at 7:07 PM |
| Abaxis Inc (ABAX) Insider Kenneth Aron Sells 1,412 Shares
www.americanbankingnews.com - March 8 at 7:06 PM |
| Abaxis Inc (ABAX) COO Sells $689,900.00 in Stock
www.americanbankingnews.com - March 8 at 6:29 PM |
| Abaxis Banks on Strong Veterinary Business Amid Margin Woes
finance.yahoo.com - March 6 at 4:52 PM |
| Factors of Influence in 2018, Key Indicators and Opportunity within Cypress Semiconductor, Abaxis,Inc, Universal Health Services, CASI Pharmaceuticals, Energy Transfer Partners, and Arconic — New Research Emphasizes Economic Growth
finance.yahoo.com - March 5 at 9:35 AM |
| Eaton Vance Management Sells 1,349 Shares of Abaxis Inc (ABAX)
www.americanbankingnews.com - March 4 at 12:24 PM |
| Quidel (QDEL) & Abaxis (ABAX) Head-To-Head Contrast
www.americanbankingnews.com - March 3 at 5:16 PM |
| Abaxis Inc (ABAX) Insider Achim Henkel Sells 3,600 Shares
www.americanbankingnews.com - March 1 at 3:22 PM |
| An Insight into Abaxis’s Business Segments
finance.yahoo.com - March 1 at 9:06 AM |
| Exploring Abaxis’s Financial Performance
finance.yahoo.com - March 1 at 9:06 AM |
| Abaxis Inc (ABAX) Expected to Post Quarterly Sales of $66.23 Million
www.americanbankingnews.com - February 27 at 8:06 AM |
| Why Is Abaxis (ABAX) Up 6.5% Since Its Last Earnings Report?
finance.yahoo.com - February 26 at 9:17 AM |
| Abaxis Inc (ABAX) Shares Sold by Comerica Bank
www.americanbankingnews.com - February 26 at 6:10 AM |
| Pinebridge Investments L.P. Has $1.45 Million Stake in Abaxis Inc (ABAX)
www.americanbankingnews.com - February 25 at 9:30 AM |
| Abaxis Inc (ABAX) Expected to Post Earnings of $0.32 Per Share
www.americanbankingnews.com - February 25 at 8:30 AM |
| Abaxis, Inc. to Present at the Bank of America Merrill Lynch Animal Health Summit and the Raymond James 39th Annual Institutional Investors Conference
finance.yahoo.com - February 22 at 9:14 AM |
| Abaxis Inc (ABAX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 20 at 9:34 PM |
| Critical Comparison: Abaxis (ABAX) & Invivo Therapeutics (NVIV)
www.americanbankingnews.com - February 19 at 1:20 PM |
| Cytosorbents (CTSO) and Abaxis (ABAX) Critical Analysis
www.americanbankingnews.com - February 15 at 3:18 AM |
| Abaxis Inc (ABAX) Expected to Announce Quarterly Sales of $66.23 Million
www.americanbankingnews.com - February 10 at 6:34 AM |
| Abaxis (ABAX) PT Raised to $48.00 at Bank of America
www.americanbankingnews.com - February 8 at 1:30 PM |
| Abaxis (ABAX) & Neovasc Inc (US) (NVCN) Critical Analysis
www.americanbankingnews.com - February 7 at 3:08 AM |
Abaxis (NASDAQ:ABAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Abaxis (NASDAQ:ABAX) Income Statement, Balance Sheet and Cash Flow Statement
Abaxis (NASDAQ ABAX) Stock Chart for Friday, April, 20, 2018
Loading chart…
